{"disease":{"id":"bladder-overactive","name":"bladder overactive"},"drugs":{"marketed":[{"drug_id":"mirabegron","indication_name":"Bladder muscle dysfunction - overactive","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Myrbetriq","generic_name":"MIRABEGRON","company_name":"Apgdi","drug_phase":"marketed","molecular_target":"Beta-3 adrenergic receptor","drug_class":"beta3-Adrenergic Agonist [EPC]","quality_score":71,"revenue":"1800","mechanism":"Myrbetriq works by activating the beta-3 adrenergic receptor in the bladder muscle, leading to relaxation and improved bladder control."},{"drug_id":"trospium","indication_name":"Bladder muscle dysfunction - overactive","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Sanctura","generic_name":"TROSPIUM","company_name":"AbbVie","drug_phase":"marketed","molecular_target":"Muscarinic acetylcholine receptor M3","drug_class":"Cholinergic Muscarinic Antagonist","quality_score":63,"revenue":null,"mechanism":"Sanctura works by blocking the action of a chemical called acetylcholine at the M3 receptor in the bladder muscle, reducing muscle contractions and urgency."},{"drug_id":"vesicare","indication_name":"Bladder muscle dysfunction - overactive","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Vesicare","company_name":"University of California, Irvine","drug_phase":"discontinued","molecular_target":"Muscarinic acetylcholine receptor M1, Muscarinic acetylcholine receptor M2, Muscarinic acetylcholine receptor M3","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"butacaine","indication_name":"Bladder muscle dysfunction - overactive","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Butyn","generic_name":"BUTACAINE","company_name":"","drug_phase":"marketed","molecular_target":"Sodium channel alpha subunits; brain (Types I, II, III)","drug_class":"butacaine","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"imidafenacin","indication_name":"Bladder muscle dysfunction - overactive","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Uritos","generic_name":"IMIDAFENACIN","company_name":"","drug_phase":"marketed","molecular_target":"Muscarinic acetylcholine receptor M3","drug_class":"","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"toviaz","indication_name":"Bladder muscle dysfunction - overactive","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Toviaz","generic_name":"Fesoterodine Fumarate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Muscarinic acetylcholine receptor M2","drug_class":"fesoterodine","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"fesoterodine","indication_name":"Bladder muscle dysfunction - overactive","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Toviaz","generic_name":"FESOTERODINE","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Muscarinic acetylcholine receptor M2","drug_class":"fesoterodine","quality_score":44,"revenue":null,"mechanism":""},{"drug_id":"solifenacin","indication_name":"Bladder muscle dysfunction - overactive","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vesicare","generic_name":"SOLIFENACIN","company_name":"Astellas Pharma","drug_phase":"marketed","molecular_target":"Muscarinic acetylcholine receptor M1","drug_class":"Cholinergic Muscarinic Antagonist","quality_score":80,"revenue":null,"mechanism":"Vesicare works by blocking the action of a chemical called acetylcholine at the muscarinic receptors in the bladder muscle, reducing muscle contractions and urgency."},{"drug_id":"darifenacin","indication_name":"Bladder muscle dysfunction - overactive","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Enablex","generic_name":"DARIFENACIN","company_name":"AbbVie","drug_phase":"marketed","molecular_target":"Muscarinic acetylcholine receptor M3","drug_class":"Cholinergic Muscarinic Antagonist","quality_score":80,"revenue":null,"mechanism":"Enablex works by blocking the action of a chemical called acetylcholine on the bladder muscle, which helps to relax the muscle and improve bladder control."},{"drug_id":"oxybutynin","indication_name":"Bladder muscle dysfunction - overactive","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ditropan Xl","generic_name":"OXYBUTYNIN","company_name":"Hisamitsu Pharmaceutical Co., Inc.","drug_phase":"marketed","molecular_target":"Muscarinic acetylcholine receptor M3","drug_class":"Cholinergic Muscarinic Antagonist","quality_score":75,"revenue":null,"mechanism":"Oxybutynin works by blocking the action of a chemical called acetylcholine on the bladder muscle, reducing spasms and urgency."},{"drug_id":"tolterodine","indication_name":"Bladder muscle dysfunction - overactive","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Detrol","generic_name":"TOLTERODINE","company_name":"Upjohn","drug_phase":"marketed","molecular_target":"Muscarinic acetylcholine receptor M1","drug_class":"Cholinergic Muscarinic Antagonist","quality_score":63,"revenue":null,"mechanism":"Detrol works by blocking the action of a chemical called acetylcholine at the muscarinic receptors in the bladder muscle."},{"drug_id":"oxytrol","indication_name":"Bladder muscle dysfunction - overactive","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Oxytrol","company_name":"Jewish General Hospital","drug_phase":"marketed","molecular_target":"Cytochrome P450 2C19, 5-hydroxytryptamine receptor 2B, D(3) dopamine receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":12,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT01972841","title":"This Was a Multinational Study Comparing the Efficacy and Safety of Two Medicines , Solifenacin Succinate and Mirabegron Taken Together, or Separately, or a Mock Treatment (Placebo) in Subjects With Symptoms of Overactive Bladder","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":3527,"lead_sponsor_name":"Astellas Pharma Europe B.V.","has_results":true},{"nct_id":"NCT00688688","title":"Study to Test the Long Term Safety and Efficacy of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":2792,"lead_sponsor_name":"Astellas Pharma Inc","has_results":true},{"nct_id":"NCT00689104","title":"Study to Assess the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":2336,"lead_sponsor_name":"Astellas Pharma Inc","has_results":true},{"nct_id":"NCT01908829","title":"A Trial Comparing Combination Treatment (Solifenacin Plus Mirabegron) With One Treatment Alone (Solifenacin)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":2174,"lead_sponsor_name":"Astellas Pharma Europe Ltd.","has_results":true},{"nct_id":"NCT00662909","title":"A Study to Assess Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":2149,"lead_sponsor_name":"Astellas Pharma Inc","has_results":true},{"nct_id":"NCT00912964","title":"A Study to Test the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":2030,"lead_sponsor_name":"Astellas Pharma Inc","has_results":true},{"nct_id":"NCT05652023","title":"Noninvasive Ultrasound Assessment of Detrusor Dysfunction","phase":"","overall_status":"RECRUITING","enrollment_count":2023,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT01638000","title":"A Study to Evaluate the Efficacy and Safety of Mirabegron Compared to Solifenacin in Patients With Overactive Bladder Who Were Previously Treated With Another Medicine But Were Not Satisfied With That Treatment.","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1887,"lead_sponsor_name":"Astellas Pharma Europe Ltd.","has_results":true},{"nct_id":"NCT02045862","title":"A Multinational Study Comparing the Long-term Efficacy and Safety of Two Medicines, Solifenacin Succinate and Mirabegron Taken Together, or Separately, in Subjects With Symptoms of Overactive Bladder","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1829,"lead_sponsor_name":"Astellas Pharma Europe B.V.","has_results":true},{"nct_id":"NCT02386072","title":"A Prospective, Observational, Multicenter Study of Patients Following Initiation of a New Course of Treatment for Overactive Bladder (OAB)","phase":"","overall_status":"COMPLETED","enrollment_count":1524,"lead_sponsor_name":"Astellas Scientific & Medical Affairs, Inc.","has_results":false},{"nct_id":"NCT01314872","title":"A Study of the Efficacy and Safety of Vibegron (MK-4618) in Participants With Overactive Bladder (OAB) (MK-4618-008)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":1395,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT01340027","title":"A Study to Evaluate the Efficacy, Safety and Tolerability of Mirabegron and Solifenacin Succinate Alone and in Combination for the Treatment of Overactive Bladder","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":1307,"lead_sponsor_name":"Astellas Pharma Europe B.V.","has_results":true},{"nct_id":"NCT00966004","title":"A Study to Evaluate Safety and Efficacy of YM178 in Patients With Overactive Bladder","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1139,"lead_sponsor_name":"Astellas Pharma Inc","has_results":false},{"nct_id":"NCT01043666","title":"A Study of YM178 in Subjects With Symptoms of Overactive Bladder","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1126,"lead_sponsor_name":"Astellas Pharma Inc","has_results":false},{"nct_id":"NCT03807024","title":"Age-specific Prevalence and Comparisons of UDS and Bladder Diary Between OAB-wet and -Dry Women","phase":"","overall_status":"COMPLETED","enrollment_count":1071,"lead_sponsor_name":"National Taiwan University Hospital","has_results":false},{"nct_id":"NCT02320773","title":"A Prospective Non-interventional Study in Overactive Bladder (OAB) Patients Prescribed Betmiga® as Part of Routine Clinical Practice","phase":"","overall_status":"COMPLETED","enrollment_count":863,"lead_sponsor_name":"Astellas Pharma Europe Ltd.","has_results":false},{"nct_id":"NCT00527033","title":"A Study of YM178 in Patients With Symptomatic Overactive Bladder","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":842,"lead_sponsor_name":"Astellas Pharma Inc","has_results":false},{"nct_id":"NCT07494864","title":"Effects of Microbiological and Immunological Factors on the Lower Urinary Tract","phase":"","overall_status":"RECRUITING","enrollment_count":800,"lead_sponsor_name":"University of Zurich","has_results":false},{"nct_id":"NCT03560778","title":"Comparisons of Urodynamic, Bladder Diary, Quality of Life Parameters Between OAB-wet and OAB-dry Female Patients","phase":"","overall_status":"COMPLETED","enrollment_count":623,"lead_sponsor_name":"National Taiwan University Hospital","has_results":false},{"nct_id":"NCT04981054","title":"BO and DO in Women With Cystocele Before and After Cystocele Repair","phase":"","overall_status":"COMPLETED","enrollment_count":483,"lead_sponsor_name":"National Taiwan University Hospital","has_results":false},{"nct_id":"NCT03043287","title":"Voiding Efficiency, a Predictor of Clean Intermittent Catheterization (CIC)","phase":"","overall_status":"COMPLETED","enrollment_count":420,"lead_sponsor_name":"Allergan","has_results":false},{"nct_id":"NCT06479720","title":"Efficacy of Solifenacin or Mirabegron With Local Estrogen Versus Combination Pharmacotherapy for Overactive Bladder","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":300,"lead_sponsor_name":"Mackay Memorial Hospital","has_results":false},{"nct_id":"NCT05968885","title":"Evaluation the Efficacy Between Botox Injection and Combination Pharmacotherapy in Patients With Detrusor Overactivity","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":300,"lead_sponsor_name":"Mackay Memorial Hospital","has_results":false},{"nct_id":"NCT01604928","title":"Study to Test the Efficacy and Safety of YM178 in Subjects With Symptoms of Overactive Bladder","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":260,"lead_sponsor_name":"Astellas Pharma Europe B.V.","has_results":false},{"nct_id":"NCT02820844","title":"Efficacy and Safety of GSK1358820 in Subjects With Overactive Bladder","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":250,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT07114640","title":"The Effect of Nighttime Mirabegron, Solifenacin, Tolterodine, or Oxybutynin on Nocturia, Sexual Function, Autonomic Function, and Lower Urinary Tract Blood Flow Perfusion in Women With Overactive Bladder Syndrome: Randomized Controlled Trial","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":220,"lead_sponsor_name":"Far Eastern Memorial Hospital","has_results":false},{"nct_id":"NCT05250908","title":"INTIBIA Pivotal Study","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":208,"lead_sponsor_name":"Coloplast A/S","has_results":false},{"nct_id":"NCT07209397","title":"Detrusor Nerve Radiofrequency Ablation for Overactive Bladder in Women","phase":"NA","overall_status":"RECRUITING","enrollment_count":202,"lead_sponsor_name":"InMode MD Ltd.","has_results":false},{"nct_id":"NCT06197295","title":"Efficacy of Combined Pharmacotherapy Versus Solifenacin With Vaginal Estrogen Cream for Women With Detrusor Overactivity","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":200,"lead_sponsor_name":"Mackay Memorial Hospital","has_results":false},{"nct_id":"NCT06210477","title":"Association With Low Compliance Bladder in Women With LUTS","phase":"","overall_status":"COMPLETED","enrollment_count":200,"lead_sponsor_name":"National Taiwan University Hospital","has_results":false},{"nct_id":"NCT01565707","title":"A Study to Investigate How Effective and Safe Solifenacin Succinate Suspension is in Treating Children/Adolescents Aged 5 to Less Than 18 Years With Symptoms of Overactive Bladder (OAB) Compared to a Non-active Drug","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":189,"lead_sponsor_name":"Astellas Pharma Europe B.V.","has_results":true},{"nct_id":"NCT06201013","title":"Vitamin D Treat-to-Target Strategy for Children With Overactive Bladder-Wet","phase":"NA","overall_status":"RECRUITING","enrollment_count":180,"lead_sponsor_name":"Children's Hospital of Chongqing Medical University","has_results":false},{"nct_id":"NCT04420533","title":"Comparative Study Between Behavior Therapy and Behavior Therapy Plus Mirabegron in Sexually Active Men With OAB Symptoms","phase":"NA","overall_status":"COMPLETED","enrollment_count":150,"lead_sponsor_name":"Chang Gung Memorial Hospital","has_results":false},{"nct_id":"NCT01655069","title":"A Study to Investigate How Safe and Effective Solifenacin Solution is in Treating Children/Adolescents With Symptoms of Overactive Bladder (OAB) Who Completed Study 905-CL-076","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":148,"lead_sponsor_name":"Astellas Pharma Europe B.V.","has_results":true},{"nct_id":"NCT03435991","title":"Experience Sampling Method in OAB Patients","phase":"","overall_status":"UNKNOWN","enrollment_count":132,"lead_sponsor_name":"Maastricht University Medical Center","has_results":false},{"nct_id":"NCT03052764","title":"Evaluation of an Alternative Injection Paradigm for OnabotulinumtoxinA (BOTOX®) in the Treatment of Overactive Bladder in Patients With Urinary Incontinence","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":120,"lead_sponsor_name":"Allergan","has_results":true},{"nct_id":"NCT05308979","title":"Intradetrusor Botulinum Toxin A for OAB Via 1 Versus 10 Injections: A Randomized Clinical Trial","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":116,"lead_sponsor_name":"University of California, Irvine","has_results":true},{"nct_id":"NCT05157295","title":"Comparing Number of Injection Sites of In-office Intravesical Onabotulinumtoxin A Treatments for Overactive Bladder: A Randomized Controlled Trial","phase":"PHASE4","overall_status":"UNKNOWN","enrollment_count":100,"lead_sponsor_name":"Augusta University","has_results":false},{"nct_id":"NCT05719285","title":"Prophylactic Antibiotic Administration for Bladder OnabotulinumtoxinA Injection","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":100,"lead_sponsor_name":"The Cleveland Clinic","has_results":true},{"nct_id":"NCT03520166","title":"Use of Medium Frequency Electrotherapy in the Treatment of OAB, LUTS and Pelvic Pain","phase":"NA","overall_status":"COMPLETED","enrollment_count":100,"lead_sponsor_name":"Fisioterapia Pélvica Avanzada Madrid, SRL","has_results":false},{"nct_id":"NCT03681678","title":"Laser Therapy for Treatment of Urogenital Symptoms in Women","phase":"","overall_status":"COMPLETED","enrollment_count":100,"lead_sponsor_name":"Corewell Health East","has_results":true},{"nct_id":"NCT05688644","title":"Sacral Neuromodulation in Neurogenic Patients","phase":"","overall_status":"UNKNOWN","enrollment_count":100,"lead_sponsor_name":"Omri Schwarztuch Gildor","has_results":false},{"nct_id":"NCT05572918","title":"Developing a Simple Test to Diagnose Overactive Bladder","phase":"","overall_status":"UNKNOWN","enrollment_count":100,"lead_sponsor_name":"Teesside University","has_results":false},{"nct_id":"NCT05328011","title":"Targeting Microbiota in Female Overactive Bladder Syndrome","phase":"","overall_status":"UNKNOWN","enrollment_count":100,"lead_sponsor_name":"Medical University of Vienna","has_results":false},{"nct_id":"NCT06921915","title":"Efficacy of Animated Videos to Foster Healthy Bladder Behaviors in Community Women","phase":"NA","overall_status":"COMPLETED","enrollment_count":90,"lead_sponsor_name":"Kathleen O'Connell","has_results":false},{"nct_id":"NCT06508944","title":"Efficacy of Vaginal 17β-Estradiol on the Urinary Storage Symptoms in Postmenopausal Women","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":86,"lead_sponsor_name":"Mahidol University","has_results":false},{"nct_id":"NCT04270526","title":"Minimizing Pain During Office Intradetrussor Botox Injection","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":85,"lead_sponsor_name":"Boston Urogynecology Associates","has_results":true},{"nct_id":"NCT05878951","title":"Examining the Effects of Intra-detrusor Botox at Time of HoLEP in Men With Overactive Bladder Symptoms","phase":"PHASE2, PHASE3","overall_status":"RECRUITING","enrollment_count":80,"lead_sponsor_name":"Northwestern University","has_results":false},{"nct_id":"NCT03727711","title":"TPTNS: Home vs Hospital Treatment for Overactive Bladder","phase":"NA","overall_status":"UNKNOWN","enrollment_count":80,"lead_sponsor_name":"NHS Greater Glasgow and Clyde","has_results":false},{"nct_id":"NCT06933407","title":"Elastographic Assessment of Suburethral Tissue in Continent and Incontinent Women","phase":"","overall_status":"RECRUITING","enrollment_count":80,"lead_sponsor_name":"Szeged University","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}